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Summsl'y 
CD4 is a membrane glycoprotein on T lymphocytes that binds to the same peptide:major histocom- 
patibility complex (MHC) class II molecule recognized by the antigen-specific receptor (TCR), 
thereby stabilizing interactions between the TCR and peptide:MHC class  II complexes and 
promoting the localization of the src family tyrosine kinase p56  lck into the receptor complex. 
Previous studies identified a solvent-exposed loop on the class II 82 domain necessary for binding 
to CD4 and for eliciting CD4 coreceptor activity. Here, we demonstrate that a second surface- 
exposed segment of class II is also critical for CD4 function. This site is in the ce2 domain, 
positioned in single class II heterodimers in such a way that it cannot simultaneously interact 
with the same CD4 molecule as the 82 site. The ability of mutations at either site to diminish 
CD4 function therefore indicates that specifically organized CD4 and/or MHC class II oligomers 
play a critical role in coreceptor-dependent T  cell activation. 
C 
D4  is  an integral membrane glycoprotein that  func- 
tions as a coreceptor for c~/8 TCRs specific for MHC 
class II molecule:peptide complexes (1-3). It is able to bind 
to MHC class II proteins expressed on cell surfaces (4,  5) 
and can interact simultaneously with the TCR and MHC 
class II during T  cell interactions with antigen-presenting 
cells (6-9), stabilizing interactions between these molecules. 
In addition, CD4 promotes the localization of the src family 
tyrosine kinase p56  ~k in the receptor complex (10, 11). These 
two functions of CD4 regulate this molecule's contribution 
to antigen-specific thymic selection (12) and peripheral T cell 
activation (13, 14). In T cells restricted by MHC class I mol- 
ecules, CD8 performs functions similar to those of CD4 in 
MHC class II-restricted T  cells (15,  16). 
MHC class II glycoproteins that interact with CD4 are 
heterodimers consisting of two non-covalently associated in- 
tegral membrane polypeptide chains, oe and 8  (17, 18). Both 
chains fold to form two distinct protein domains, with the 
highly polymorphic c~1 and ~1 domains combining to form 
a single membrane-distal antigen-binding region (19, 20). Con- 
versely, the membrane-proximal domains are relatively non- 
polymorphic  and  consist  of typical  immunoglobulin-like 
domains that  are frequently involved in receptor:counter- 
receptor interactions between hematopoietic cells. 
Previous studies identified a solvent-exposed loop on the 
membrane-proximal 82 domain of class II molecules that is 
necessary for binding to CD4 and for eliciting CD4 coreceptor 
activity (21, 22). Here, we demonstrate that a second surface- 
exposed segment of the class II heterodimer located in the 
ce2 domain is also critical for CD4 function. This site is posi- 
tioned in such a way that it does not appear able to simul- 
taneously interact with the same CD4 molecule as the 82 
site. These results impact on our understanding of coreceptor- 
dependent TCR complex formation during T cell activation, 
indicating the importance of organized CD4 and/or MHC 
class II oligomerization. The class II 82 and ce2 regions that 
interact with CD4 are brought next to one mother in the 
recently described crystallographic structure of the class II 
"dimer of dimers" (20), suggesting an intriguing molecular 
model for this oligomerization event. 
Materials  and Methods 
Cells.  DO.11.10 cells (23) were transduced with cDNA expres- 
sion vectors encoding the human CD4, mouse CD4, or mouse 
CD8ce coreceptors and selected as described (22). The 171.3 T cell 
hybridoma lines were kindly provided by Drs. Glaichenhaus and 
Shastri (24). All hybridomas were grown in RPM11640 containing 
10% heat-inactivated fetal calf serum, 2 mM L-glutamine,  0.1 mM 
nonessential amino acids, 1 mM sodium pyruvate, 10 mM Hepes, 
50/~M 2-mercaptoethanol, and 250/~g/ml of the neomycin ana- 
logue G418 at 37~  and 5% CO2. Murine DAP.3 L cells were 
transfected with  wild-type or mutant AoY cDNA expression 
plasmid DNA (5/~g) together with wild-type A~  d cDNA expres- 
sion plasmid DNA (5/Lg) and the selective marker pMo-neo (0.4 
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nous populations of  cells expressing  high levels  of  wild-type or mu- 
tant AtriA/3  a heterodimers were selected by antibody-mediated 
magnetic bead sorting (22). The structural integrity of mutant 
A~A~  d molecules was determined by antibody dilution  assays 
(26) using the mAbs K24-199 (27) (specific  for polymorphic  residues 
in the otl domain), MK-D6 (28) (specific  for polymorphic residues 
in the/31 domain), and M5/114 (29) (specific for a/$1 epitope of 
assembled a/B heterodimers). Transfected  L cells were maintained 
in DMEM containing the same additives as described above for 
KPMI 1640 at 37~  and 10% CO2. 
Mutagenesis.  Mutations were generated either by the gapped 
heteroduplex method (22, 30) for S125G, S127T, V128A, G131A, 
Y133S, and ~E137A.V142A, or by PCK and splicing by overlap 
extension (22, 31). PCR and splicing by overlap extension condi- 
tions were as follows: 1 min at 94~  1 min at 40~  1 min at 
50~  2 min at 72"C for 30 cycles  followed by one cycle of 7 min 
at 72~  in a DNA thermal cycler  (Ericomp, Inc., San Diego, CA). 
Mutant cDNAs were subcloned into the EcoKI site of the expres- 
sion vector PeEXV-3 (32), and sequenced from double-stranded 
templates either by dideoxynucleotide  sequencing using Sequenase 
version 2.0 T7 DNA polymerase (U.S. Biochemical  Corp., Cleve- 
land, OH) and the Multiwell sequencing kit (Amersham Corp., 
Arlington Heights, IL) or by cycle sequencing using Taq DNA 
polymerase (Perkin-Elmer  Corp., Norwalk, CT). Cycle sequencing 
reactions were analyzed  on a DNA sequence analyzer  (model  373A; 
Applied Biosystems, Inc., Foster City, CA). 
Functional T CellAssays.  DO.11.10  hybridoma  cells  were stimu- 
lated with the synthetic ovalbumin  peptide 323-339 and 171.3 cells 
with the bacterial superantigen  staphylococcal  enterotoxin A (Toxin 
Technology,  Sarasota, FL). Duplicate cultures of T hybridoma cells 
(5  x  104 cells/well) with AetdABa-expressing L cells (5 x  104 
cells/well) in fiat-bottomed 96-well plates in a total vol of 200 #I 
of complete KPMI 1640 medium containing the indicated antigen 
concentrations  were cultured for 24 h. Culture supematants  of  dupli- 
cate wells were pooled and assayed for Ib2 and IL-3 content by 
their ability to support the proliferation of the indicator cell lines 
CTLL-2 and FD.C/1, respectively. For each culture supernatant, 
three threefold (1:6 to 1:54 final concentration for IL-2) or four 
fourfold (1:38 to 1:3,056 final  concentration for IL-3)  dilutions were 
tested in triplicate on 1 x  104 CTLL-2 or 5  x  103 FD.C/1 cells. 
Incubations were done in fiat-bottomed 96-well plates in a total 
volume of 200 #1 complete RPMI 1640 for 28 and 44 h, respec- 
tively. For the last 4 h of the incubation, 1 #Ci of [3H]thymidine 
was added. Cells were then harvested with a harvester (Filtermate 
196; Packard Instrument Co., Inc., Meriden, CT) and [3H]thymi- 
dine incorporation was determined using a direct beta counter (Ma- 
trix 9600; Packard). Lymphokine  units were calculated  as described 
(26), and are expressed in units per ml-t. To test for experimental 
rather than biological  variability,  select  assays  were cultured in tripli- 
cate and supernatants were carried through separately to obtain 
triplicate measurements of the cytokine response per concentra- 
tion point. At lymphokine concentrations below those giving the 
maximum proliferation of the indicator ceils, the results were es- 
sentially identical to those obtained when replicate supernatants 
were pooled before determining lymphokine concentrations. In ad- 
dition, there were no differences  in the qualitative  conclusions  con- 
cerning the effects of individual mutations whether lymphokine 
concentrations were determined from dilution curves or the counts 
per minute incorporated at each supernatant dilution were plotted 
against antigen concentration. Lymphokine unit assays, however, 
more accurately reflected differences  in responses at high antigen 
concentrations. 
Molecular Modeling.  The MHC class II images were generated 
using Quanta software  (Polygen  Corp., Waltham, MA) on a Silicon 
Graphics workstation (Mountain View, CA) from coordinates  cor- 
responding to HLA-DK1 as determined by Brown et al. (20). 
Results and Discussion 
Experimental  Approach.  Structural homologies (19, 20, 
33-36) and similar functions (37) of MHC class I and class 
II molecules suggest analogies in the mechanism of CD8- 
MHC class I and CD4-MHC class II interactions. Indeed, 
the previous identification of the class II/$2 domain's interac- 
tion with CD4 (amino acid residues  137-143)  was based in 
part on the assumption that the binding site for CD4 might 
lie in a position analogous to the CD8- binding site on MHC 
class I molecules. An x-ray crystallographic structure had been 
determined for the human class I molecule, HLA-A2 (38), 
and a binding site for CD8 on the ct3 domain of HLA-A2 
had been identified (39) before these published CD4 studies. 
Although the class II/$2 domain was the predicted homo- 
logue of the class I c~3 domain, the lack of a crystallographic 
structure for class II at that time left open the possibility 
that the class II or2 domain might actually be the relevant 
domain for CD4 binding. Sequence alignment of the/$2 do- 
main of MHC class II with the class I c~3 domain yielded 
a high degree of similarity, but alignment of the class II o~2 
domain with the MHC class I-associated/$2-microglobulin 
was not as good. In fact, the MHC class II o~2 domain aligns 
better with the class I o~3 domain than with/$2-microglob- 
ulin. We therefore introduced mutations in both the class 
II/$2 and the ol2 domains. Analysis of mutants carrying amino 
acid substitutions in a surface-exposed  loop of the/$2 do- 
main rapidly revealed the presence of a critical CD4 contact 
site, but several clustered mutations in the o~2 domain also 
diminished function with CD4. We have now carefully ana- 
lyzed this highly conserved second region comprising Ao~ 
amino acids 125-133 (numbering of residues is according to 
Kabat et al.[40]). 
Single or double mutations were made in an Ac~  d cDNA 
throughout this region. Two types of mutations were gener- 
ated: human for mouse substitutions and alanine replacements. 
In addition, to sterically interfere with CD4-MHC class II 
interactions, we attempted to introduce potential N-linked 
glycosylation sites at positions 127 and 129 of the Ao~  a mol- 
ecule. These mutants, however,  were not expressed  on the 
cell surface of transiently transfected COS or stably trans- 
fected mouse L cells. On the other hand, the corresponding 
control constructs carrying an asparagine residue at positions 
127 or 129 and an alanine or glycine residue at positions 129 
or 131, respectively, were surface expressed, and are included 
in this analysis. 
The mutant Aot  d cDNA constructs were cotransfected 
into L cells together with a cDNA construct encoding wild- 
type A/$  a and a plasmid carrying a neomycin-resistance gene. 
Stable transfectants were selected in G418-containing medium, 
and cells expressing high levels of the A a ct//$ heterodimer 
were isolated by antibody-mediated magnetic bead sorting. 
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efficient surface MHC class II expression. These mutant het- 
erodimers reacted appropriately with a panel of monoclonal 
anti-A  a antibodies,  indicating that  the mutations did not 
grossly affect the folding and conformation of the class II 
c~ chain or the assembled or3 heterodimer (data not shown). 
The  various  transfected  L  cells were used  as  antigen- 
presenting cells for the stimulation of two sets of T cell hy- 
bridomas, derived from the parental lines DO.11.10 (23) and 
171.3 (24). Members of each set express the same TCR, but 
differ in coreceptor expression, having on their surface either 
human CD4 (hCD4), mouse CD4 (mCD4), mouse CD8 
(mCD8), or no coreceptor at all. The DO.11.10 hybridoma 
responds to stimulation by APC plus peptide antigen with 
lymphokine secretion even in the absence of CD4 expres- 
sion. It is therefore possible to selectively assess the effect of 
sequence changes in Aot  d on the capacity of the or/3 het- 
erodimer to elicit CD4 coreceptor  function by comparing 
the responses to mutant vs. wild-type class II molecules of 
DO.11.10 cells with different coreceptor expression. Muta- 
tions with selective effects on CD4 coreceptor function but 
without effects on peptide binding or TCR recognition will 
not affect the responses of the CD4-negative T cell hybrid- 
omas, which therefore can serve as a control to render this 
assay independent of the precise level of dass II expression 
on the individual  transfectant L cell lines, or of differences 
in the absolute level of cytokine production by the individual 
T hybridoma cell lines. In contrast,  the 171.3 hybridoma re- 
quires CD4 expression for responses to peptide or toxin. By 
using transfectants  with comparable  levels of cell-surface  MHC 
class II expression, the hybridoma set based on 171.3 can be 
used to confirm data obtained using the DO.11.10-based set 
of hybridomas. This is the same assay  used previously to iden- 
tify the CD4 interaction site on the class II/32 domain (22). 
Effects of Mutations.  In the presence of wild-type Ac~A3  d, 
DO.11.10 T cells expressing either hCD4 or mCD4 secreted 
more IL-3 than mCD8-bearing cells (Fig, 1, A  and F, and 
Fig.  2 A),  responding more vigorously than the mCDS- 
expressing line at any given dose of antigen. Substitution of 
glycine for serine at position 125 in the ol chain strongly re- 
duced the response of the mCD4-expressing  DO.11.10 cells 
at all antigen concentrations,  but did not affect the response 
of the hCD4-bearing cells (Fig. 1 C). This mutation is an 
example of an isotypic substitution at an amino acid highly 
conserved between alleles of a particular isotype, with serine 
occurring in all alleles of Aot, and glycine in Ec~ (as well as 
all human class II MHC isotypes). This finding is consistent 
with functional data suggesting CD4 interacts less well with 
Ec~E3 than with AccA3 (41). Another mutation of this type, 
substitution of serine for tyrosine at position  133, had no 
effect on either the hCD4 or the mCD4-expressing hybrid- 
omas (Fig. 3). Alanine substitution at positions  129 (Fig. 2 
C) and 131 (Fig. 1 D) in the oe chain substantially decreased 
responses from both hCD4 and mCD4-bearing cells, as did 
substitution of asparagine for threonine at position 129 (Figs. 
1 G and 2 D), and two different double mutations also in- 
volving residue 129 (Figs. 1 H, 2 E, and 3). In contrast, the 
capacity of these mutants to elicit responses from the mCD8- 
expressing DO.11.10 cells remained wild type-like. As a com- 
parison,  we have included the previously described double 
alanine mutation in the AaB2 domain at positions  137 and 
142  (Fig. 1J), which abrogates CD4 coreceptor function 
in this assay (22). Mutations decreasing CD4 function in these 
DO.11.10 experiments also reduced cytokine production by 
both hCD4- and mCD4-expressing 171.3 cells relative to stim- 
ulation with wild-type ActA/~ molecules (Fig. 1, K-N). 
Asparagine substitution of threonine 129 drastically  reduced 
function with both hCD4 and mCD4 (Figs. 1 G and 2 D). 
Function with hCD4 was also eliminated by combining the 
alanine substitution at position 125 with one at position 129 
(Figs. 1 H and 2 E). Conversely, substituting glycine for serine 
at position 125 (a change that introduces the conserved human 
residue at this position) dramatically decreased function with 
mCD4, but did not affect function with hCD4. To deter- 
mine the individual contributions of alanine substitutions  at 
positions  125 and 129, we compared the former with the 
double alanine mutation and the asparagine for threonine sub- 
stitution at 129 (Fig. 2). This experiment demonstrated the 
major contribution of the alanine for serine substitution at 
125 to the decrease in function with hCD4, and the equiva- 
lency of alanine and asparagine substitutions  at  129. 
The effects of mutations in the ol2 domain of I-A  a ap- 
peared greatest at low to moderate antigen concentrations. 
Mutations judged to decrease function with CD4 reduced 
responses by CD4 + T  hybridomas to a level equal or only 
slightly higher than that seen with the mCD8 + control hy- 
bridoma cells. As seen in some of the antigen dose-response 
curves depicted in Fig. 1, the effects of a partial loss of MHC 
class II-induced CD4 function could be overcome at very 
high antigen concentrations.  To standardize data from mul- 
tiple experiments in which absolute responses varied, we used 
a transformation formula that accounts for the range in the 
dose-response curve covered by low to moderate antigen con- 
centrations.  This formula gives an estimate of the residual 
CD4 coreceptor function induced by the respective mutant 
AotdA~ d molecule with wild type-like function represented 
by a fractional value of 1 and a value of 0 given to mutant 
AotdA/~ d molecules that fail to induce an increased response 
by the CD4 + T  hybridoma ceUs as  compared with  the 
CD8 + control calls. The fractional CD4 coreceptor function 
was  defined  as:  F  =  log f  [mutant  Ac~aABd]/log f 
[Ac~dABd]; wherefrepresents the ratio between the antigen 
concentration necessary  to  half-maximally  stimulate  the 
CD8 + control T hybridoma and the antigen concentration 
required to cause equal cytokine secretion by T hybridoma 
cells bearing either mCD4 or hCD4. 
Fig. 3 summarizes the results of several independent ex- 
periments of the type illustrated in Figs. 1 and 2 using the 
transformation formula  just described. In each individual ex- 
periment, this formula attributes a value of F  =  1 to wild- 
type Ao~dA/3  d.  The  shaded  area in  the  panels of Fig.  3 
represents the range of F values seen in repeated experiments 
with mutations we judge to have wild-type function with 
CD4, because they led to only small effects of inconsistent 
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Figure  1.  Selective mutations in the region of Ac~ formed by amino acids 125-133 decrease CD4 coreceptor function in T cell assays. Antigen dose- 
response curves for murine T hybridoma DO.11.10 cells expressing either mouse (closed circles) or human CD4 (open circles), or mouse CD8 (open squares) 
after stimuhtion with antigen (ovalbumin peptide 323.339) presented by wild-type or mutant Ac~dA/~  d transfected  L cells (A-J), and for hybridoma 
171.3 cells expressing either mCD4 (closed circles) or hCD4 (open circles) after stimulation with staphylococcal enterotoxin A and similar transfectants 
(K-N).  Coreceptor-negative 171.3 cells did not secrete lymphokine at any concentration of antigen tested. Numbering of residues is according to Kabat 
et al. (40). Mutants are identified by the wild-type residue at the indicated position followed by the new residue present in the mutant protein. Data 
in panels presented in one row are from the same experiment. Results for the following transfectants are shown: (A) wiki-type A~IA~d; (B) Ao~S127T; 
(C) AaS125G; (D) AaG131A. In E, dose-response  curves for the mCD8 + DO.11.10  stimulated with antigen plus wild-type or mutant Ao~A~  d- 
expressing L cells are depicted to show the comparable capacity of the different Aa,  dA~  d molecules  to provide CD4-independent T cell stimulation 
(closed circles, wild-type AotdA~d; open circles, Ao~S125G; squares, AotS127"l~ triangles,  AotG131A);  (F)  wild-type Acr~A/3d; (G)  A~T129N;  (H) 
AaS125A.T129A; (I) AaV132A; (/) the previously described mutant A~ED7A.V142A is shown for comparison; (K) wild-type Ao~A~a; (L) AotS125G; 
(M) Ac~T129A; (N) AaY133S. In each row of panels, one mutation that did not affect function with either mCD4 or hCD4 is shown (/3, I, and 
N). For experiments with the 171.3 hybridomas, wild-type and mutant transfectants were sdected for closely matched levels of surface class II expression. 
direction (e.g., 0.78-1.1  for $127T with mCD4; 0.96-1.18 
for V132A with mCD4). Bars that do not reach these shaded 
areas or extend beyond them therefore identify mutations that 
consistently  affect function with CD4 in a single direction 
(decrease or increase, respectively) and to an extent greater 
than the experimental variability in this system. The data in- 
dicate that amino acids 125-131 of  Ac~ are part of a site neces- 
sary for optimal class II-dependent CD4 coreceptor func- 
tion. Threonine 129 appeared to be particularly  important 
for mediating this interaction,  because both alanine substi- 
tution and the relatively conservative asparagine replacement 
drastically reduced function with both hCD4 and mCD4. 
Glycine for serine substitution at position 125 drastically re- 
duced function with mCD4, but did not affect function with 
hCD4.  On the other hand, alanine for serine substitution 
at 125 affected function with both. The differential effect of 
glycine vs. alanine at position 125 on human CD4 vs. mouse 
CD4 function could reflect the coevolution  of the human 
coreceptor and class II for proper interaction involving this 
site directly. Alternatively, structural data indicate that residues 
125-133 are part of a surface-exposed loop between the C 
and D strands of the o~2 domain (20) (Fig. 4 A). Both ends 
of this loop are defined by glycines in most class II mole- 
cules, and mutating residues 125 and 131 may affect the overall 
conformation of the loop. 
Several of the substitutions augmented function with CD4. 
For example, substitution of serine for tyrosine 133 strongly 
enhanced function with both mouse and human CD4. Serine 
is the amino acid occurring at this position in all alleles of 
HLA-DK and DQ, whereas tyrosine at this position is con- 
served among alldes of I-A. The increase in function resulting 
from the serine for tyrosine substitution may be a reflection 
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Figure 2.  Mutating amino acids 125 and 129 of Ac~ causes drastic decreases  in CD4 coreceptor  function. Antigen dose-response  curves for T hy- 
bridoma DO.11.10 cells after stimulation with ovalbumin peptide 323-339 and wild-type or mutant Ac~aAB  a transfected  L cells are shown. For an 
explanation of symbols refer to Fig. 1. 
of the higher affinity of human CD4 for human class II com- 
pared to mouse CD4 and mouse class II (21,  42),  and the 
contribution of serine at this position to stronger binding 
between these proteins.  A  simple structural explanation is 
not as readily apparent for the ability of conservative substi- 
tutions $127T and V128A to sdectivdy enhance function with 
human but not mouse CD4. 
Structural and Functional Implications.  Computer docking 
studies show that the dongated, rigid structure of the CD4 
D1 and D2 domains involved in interaction with class II (43, 
44) and the positioning of the 132 and a2 sites on opposite 
faces of the class II heterodimer (Fig. 4 A) prevent these crit- 
ical binding regions of single CD4 molecules from simul- 
taneously interacting with both sites on an individual class 
II molecule (Fleury, S.,  and R.  N.  Germain, unpublished 
observations). Yet the ability of either a  or B chain muta- 
tions to strongly decrease the capacity of class II molecules 
to support CD4 function indicates that both sites are required 
for inducing full CD4 coreceptor activity. Together, these 
observations provide the first evidence that during T cell ac- 
tivation by physiological ligands, CD4 and class II molecules 
must undergo a structurally precise dimerization or oligo- 
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merization for the effective contribution of CD4 to receptor- 
dependent signal transduction. 
Two different general models for the organization of the 
CD4-class II complex can be envisioned that satisfy the struc- 
tural constraints revealed by this study and the available data 
on CD4 regions affecting interaction with class II (44).  In 
the first model, two CD4 molecules would associate  with 
a single TCR-MHC class II complex, one CD4 molecule 
binding to the a2 site and the other to the/32 site ( Fig.  5 A). 
The two CD4 molecules thus would form a damp tethering 
the class II ligand to the TCR.  This would also provide a 
mechanism for activating the protein tyrosine kinase, p56 k~, 
upon monovalent TCR-MHC class II interaction, based on 
CD4 dimerization in this postulated complex. Furthermore, 
higher order oligomerization of the coreceptor-TCR-MHC 
class II units might occur, if the free face of each CD4 mole- 
cule could engage the alternative site of an adjacent, TCR- 
engaged class II molecule (Fig.  5 B). This model is consis- 
tent with data suggesting that two opposite surfaces of the 
D1-D2 segment of CD4 contribute to class II recognition 
(44), and with the possible role of such higher order oligomers 
("immunons") in lymphocyte signal transduction (45). Figure  3.  Residual coreceptor function of mouse and human CD4 in 
response  to  mutant  Ac~aA/3  d  molecules.  A  quantitative  evaluation  of 
coreceptor function with each mutant I-A molecule was derived from dose- 
response curves  as in Figs.  1 and  2 by normalizing responses of CD4 
coreceptor  positive  and  negative  T  cell hybridomas  to the responses of 
the same T cells to wild-type A~aA/3  d. The bars represent  mean values 
of two to six independent  experiments  (only one experiment  was per- 
formed for A~S125A.S127A with hCD4 + DO.11.10 cells). The shaded 
area represents the range of F values seen in independent experiments using 
mutant class II molecules considered wild-type in their function with CD4. 
784  Role for Ordered Oligomerization in T  Cell Activation Figure  5.  (A) Clamp model of CD4 function. One CD4 molecule binds 
to each of the functionally significant sites on a single MHC class II het- 
erodimer. These two CD4 molecules and the single class II-peptide com- 
plex are postulated to interact with a single T cell receptor complex (not 
shown).  (/3) Adapter model of CD4 function. As in A, two CD4 mole- 
cules bind to each T cell receptor:MHC class II/peptide complex, but the 
CD4 also can link individual class II MHC heterodimers to one another 
by bridging between the c~ and B chain sites on different  class II mole- 
cules. (C) MHC class II superdimer oligomerization by CD4 molecules 
with a single binding site for a conjoint c~2/~2  target region and a sepa- 
rate dimerization interface. 
An intriguing alternative model comes from recognizing 
that the or2 and B2 sites lie in close proximity on a single 
face of the dimer of dimers observed in crystals of the human 
class II HLA-DR1 molecule (20) (Fig. 4 B). In this configu- 
ration, the two discontinuous sites on a single class II dimer 
would now contribute to a single surface for interaction with 
CD4, possibly supporting a higher binding affinity than ei- 
ther site alone. CD4 would thus stabilize the interaction of 
the two heterodimer units of the class II "superdimer" and 
that of the associated pair of TCR complexes (Fig.  5 C). 
The mapping of regions contributing to CD4-class II inter- 
action to discrete faces of CD4 might then reflect the pres- 
ence of the actual binding surface on one face, and a possible 
dimerization interface  on the other, that could link TCR- 
superdimer complexes into large oligomers. 
A large body of literature derived primarily from antibody 
cross-linking experiments supports the importance ofcoclus- 
tering or coaggregation of CD4 and TCR for effective T  cell 
activation,  but these prior studies provided no information 
on the specific molecular associations  necessary for proper 
signaling during physiological call-cell interaction (6, 7, 15). 
The identification here of a second discrete binding site for 
CD4 on class II molecules strongly suggests that structur- 
ally specific, ordered oligomerization as opposed to general- 
ized colocalization is a key feature in the assembly of useful 
signal transduction complexes on T cells. This result extends 
to the T cell receptor-coreceptor complex the general prin- 
ciple of ligand-induced receptor dimerization/oligomeriza- 
tion as a key event in the initiation of transmembrane sig- 
naling (46). The critical role of these stable, properly assembled 
dimers or oligomers in T  cell activation also suggests that 
the partial agonist or antagonist properties of variant TCR- 
MHC:peptide complexes (47-49) may result from improper 
formation or altered stability of these critical molecular as- 
semblies  (50-53). 
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Figure  4.  (A) The two sites affecting  class II--CD4 interaction lie on opposite sides of a single MHC  class II heterodimer. The image is a side 
view of an MHC class II molecule (yellow ribbon drawing), with the residues  of both the 137-147 loop in the/32 domain and the 125-131 region in 
the or2 domain that affect interaction with CD4 shown in red. The domains of the class II molecule are labeled.  (/3) The two sites affecting  class 
II-CD4 interaction lie next to one another in the dimer of dimers crystal structure of MHC class II. The image is a side view of the dimer of dimers 
(yellow ribbon drawing), with the residues of both the 137-147 loop in the B2 domain and the 125-131 region in the or2 domain that affect interaction 
with CD4  shown in red.  The domains of each class II molecule are labeled. 
785  K•nig  et al. Address correspondence to R. N. Germain, Lymphocyte Biology Section, Laboratory of Immunology, 
National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Drive MSC 
1892, Building 10, Room  11N311, Bethesda, MD 20892-1892. 
Received for publication 10 March  1995 and in revised  form  12 May  1995. 
Re~l~llCes 
1.  Swain, S.L. 1983. T cell subsets and the recognition of MHC 
class, lmmunol. Rev. 74:129-142. 
2.  Biddison, W.E., and S. Shaw. 1989. CD4 expression and func- 
tion in HLA class II-specific  T cells. Immunol. Reu. 109:5-15. 
3.  Bierer,  B.E., B.P. Sleckman, S.E. Ratnofsky, and S.J. Burakoff. 
1989. The biologic roles of CD2, CD4,  and CD8 in T-cell 
activation. Annu.  Rev. Immunol. 7:579-599. 
4.  Doyle,  C., andJ.L. Strominger. 1987. Interaction  between CD4 
and class II MHC molecules mediates cell adhesion. Nature 
(Lond.). 330:256-259. 
5.  Clayton, L.K., M. Sieh, D.A. Pious, and E.L. Reinherz. 1989. 
Identification of human CD4 residues affecting class II MHC 
versus HIVol gp120 binding. Nature (Lond.). 339:548-551. 
6. Janeway, C.A., J. Rojo, K. Saizawa, U. Dianzani, P. Portoles, 
J. Tite, S. Haque, and B. Jones. 1989. The co-receptor func- 
tion of murine CD4. Immunol. Rev. 109:77-92. 
7. Janeway, C.A. 1992. The T cell receptor as a multicomponent 
signalling machine: CD4/CD8 coreceptors and CD45 in T 
cell activation. Annu.  Rev. lmmunol. 10:645-674. 
8.  Xu, H., and D.R. Littman. 1993. A kinase-independent  func- 
tion of Lck in potentiating antigen-specific  T cell activation. 
Cell. 74:633-643. 
9.  Vignali, D.A.A., andJ.L. Strominger. 1994. Coreceptor func- 
tion and the characteristics  of  MHC-bound peptides: a common 
link? The Immunologist. 2:112-118. 
10.  Veillette, A., M.A. Bookman, E.M. Horak, and J.B. Bolen. 
1988. The CD4 and CD8 T cell surface antigens are associated 
with the internal membrane tyrosine-protein kinase p561r 
Cell. 55:301-308. 
11.  Turner, J.M., M.H. Brodsky, B.A. Irving, S.D. Levin, R.M. 
Perlmutter, and D.R. Littman. 1990. Interaction of the unique 
N-terminal region of tyrosine kinase p561r  with cytoplasmic 
domains of CD4 and CD8 is mediated by cysteine  motifs. Cell. 
60:755-765. 
12.  yon Boehmer, H. 1994. Positive  selection  oflymphocytes. Cell. 
76:219-228. 
13.  Rudd, C., S. Helms, E.K. Barber, and S.F. Schlossman. 1989. 
The CD4/CD8:p56 ~ complex in T lymphocytes: a potential 
mechanism to regulate T-cell growth. Biochem. Cell Biol. 67: 
581-589. 
14.  Veillette, A., M.A. Bookman, E.M. Horak, L.E. Samelson, 
and J.B. Bolen. 1989. Signal transduction through the CD4 
receptor involves the  activation of the  internal  membrane 
tyrosine-protein kinase p56  lck. Nature (Lond.). 338:257-259. 
15.  Miceli, M.C., and J.R. Fames. 1993. Role of CD4 and CD8 
in T cell activation  and differentiation.  Adv. Immunol. 53:59-122. 
16.  Zamoyska,  R. 1994. The CD8 coreceptor revisited: one chain 
good, two chains better. Immunity.  1:243-246. 
17.  Kaufman,  J.F., andJ.L. Strominger. 1979. Both chains of HLA- 
DR bind to the membrane with a penultimate hydrophobic 
region and the heavy  chain is phosphorylated  at its hydrophobic 
carboxy terminus. Proa Natl. Acad. Sci. USA. 76:6304-6308. 
18.  Shackelford, D.A.,  J.F.  Kaufman, A.J. Korman,  and J.L. 
Strominger. 1982. HLA-DR antigens: structure, separation of 
subpopulations, gene cloning and function. Immunol. Rev. 66: 
133-187. 
19.  Brown, J.H., T. Jardetzky, M.A. Saper, B.  Samraoui, P.J. 
Bjorkman, and D.C. Wiley. 1988. A hypothetical model of 
the foreign antigen binding site of class II histocompatibility 
molecules. Nature (Lond.). 332:845-850. 
20.  Brown, J.H., T.S. Jardetzky, J.C.  Gorga, L.J. Stern, R.G. 
Urban, J.L. Strominger, and W.D.C. 1993. Three-dimensional 
structure of the human dass II histocompatibility  antigen FILA- 
DR1. Nature (Lond.). 364:33-39. 
21.  Cammarota, G., A. Scheirle, B. Takacs, D.M. Doran, R. Knorr, 
W. Bannwarth, J. Guardiola, and F. Sinigaglia. 1992. Identi- 
fication of a CD4 binding site on the 82 domain of HLA-DR 
molecules. Nature (Lond.). 356:799-801. 
22.  K6nig, R., L.Y. Huang, and R.N. Germain. 1992. MHC class 
II interaction with CD4 mediated by a region analogous to 
the MHC class I binding site for CD8. Nature (Lond.). 356: 
796-798. 
23.  Marrack, P., R. Endres, R. Shimonkevitz, A. Zlotnik, D. Di- 
alynas, F. Fitch, and J. Kappler. 1983. The major histocom- 
patibility complex-restricted antigen receptor on T cells. II. 
Role of the L3T4 product. J. Exl~ Med. 158:1077-1091. 
24.  Glaichenhaus,  N., N. Shastri, D.R. Littman, andJ.M. Turner. 
1991. Requirement for association of p561ck with CD4 in 
antigen-specific  signal transduction in T cells. Cell. 64:511-520. 
25.  Margnlies,  D.H., G.A. Evans, K. Ozato, R.D. Camerini-Otero, 
K. Tanaka, E. Appella, and J.G. Seidman. 1983. Expression 
of H-2D  d and H-2L  d mouse major histocompatibility antigen 
genes in L cells after DNA-mediated gene transfer.J. ImmunoL 
130:463-470. 
26.  Ronchese, F., M.A. Brown, and R.N. Germain. 1987. Struc- 
ture-function  analysis of the  AB  bin12 mutation using  site- 
directed mutagenesis and DNA-mediated gene transfer.J. Im- 
munol. 139:629-638. 
27.  Lemke,  H., G.J. HLrnmerling,  and U. H~nmerling. 1979. Fine 
specificity  analysis  with monoclonal  antibodies of antigens con- 
trolled by the major histocompatibility complex and by the 
Qa/TL region in mice. Immunol. Rev. 47:175-206. 
28.  Kappler,  J.W., B. Skidmore, J. White, and P. Marrack. 1981. 
Antigen-inducible,  H-2-restricted, interleukin-2-producing T 
cell hybridomas. Lack of independent antigen and H-2 recog- 
nition. J. Ex  F Med. 153:1198-1214. 
29.  Bhattacharya,  A., M.E. Doff, and T.A. Springer. 1981. A shared 
alloantigenic determinant on Ia antigens encoded by the I-A 
and I-E subregions: evidence for I region gene duplication. 
J. Immunol. 127:2488-2495. 
30. Dalbadie-McFarland,  G., L.W. Cohen, A.D. Riggs, C. Morin, 
K. Itakura, andJ.H. Richards. 1982. Oligonucleotide-directed 
mutagenesis as a general and powerful method for studies of 
protein function. Proc. Natl. A_cad. Sci. USA.  79:6409-6413. 
786  Role for Ordered Oligomerization in T Cell Activation 31.  Ho, S.N., H.D. Hunt, R.M. Horton, J.K. Pullen, and L.R. 
Pease. 1989. Site-directed mutagenesis by overlap extension 
using the polymerase chain reaction. Gene (Amst.).  77:51-59. 
32.  Miller, J., and R.N. Germain. 1986. Efficient  cell surface ex- 
pression of  class II MHC molecules  in the absence of  associated 
invariant chain. J. Exp. Med. 164:1478-1489. 
33.  Kaufman,  J.F., C. Auffray.  A.J. Korman, D.A. Shakelford,  and 
J. Strominger. 1984. The class II molecules of the human and 
murine major histocompatibility complex. Cell. 36:1-13. 
34.  Travers, P., T.L. Blundell, M.J. Sternberg, and W.F. Bodmer. 
1984. Structural and evolutionary analysis of HLA-D-region 
products. Nature (lAnd.).  310:235-238. 
35.  Brownstein,  N.S., and R.N. Germain. 1987. Allele-specific  con- 
trol of la molecule surface expression and conformation: im- 
plications for a general model of  Ia structure-function relation- 
ships. Proc. Natl.  Acad. Sci. USA.  84:2921-2925. 
36.  Gorga, J.C., A. Dong, M.C. Manning, R.W. Woody, W.S. 
Canghey, and J.L. Strominger. 1989. Comparison of the sec- 
ondary structures of  human class I and class II major histocom- 
patibility complex antigens by Fourier transform infrared and 
circular dichroism spectroscopy. Pro~ Natl.  Acad. Sci. USA. 
86:2321-2325. 
37.  Germain, K.N. 1994. MHC-dependent antigen processing and 
peptide presentation: providing ligands for T lymphocyte ac- 
tivation. Cell. 76:287-299. 
38.  Bjorkman, P.J., M.A. Saper, B. Samraoui, W.S. Bennett, J.L. 
Strominger, and D.C. Wiley. 1987. Structure of the human 
class I histocompatibility antigen, HLA-A2. Nature (1And.). 
329:506-512. 
39.  Salter, K.D., K.J. Benjamin, P.K. Wesley,  S.E. Buxton, T.P.J. 
Garrett, C. Clayberger,  A.M. Krensky, A.M. Norment, D.R. 
Littman, and P. Parham. 1990. A binding site for the T-cell 
co-receptor CD8 on the a3 domain of HLA-A2. Nature(lAnd.). 
345:41-46. 
40.  Kabat, E.A., T.T. Wu, H.M. Perry, K.S. Gottesman, and C. 
Foeller. 1991. Sequences of proteins of immunological interest. 
5th edition. U.S. Department of Health and Human Services, 
Public Health Service, National Institutes of  Health, Bethesda, 
MD.  1-1137. 
41.  Cosgrove, D.,  H. Bodmer, M.  Bogne, C. Benoist, and D. 
Mathis. 1992. Evaluation  of the functional  equivalence  of  major 
histocompatibility complex class II A and E complexes.J. Exit 
Med.  176:629-634. 
42.  Weber, S., and K. Karjalainen. 1993. Mouse CD4 binds MHC 
class II with extremely low affinity. Int. Immunol. 5:695-698. 
43.  Wang, J.H., Y.W. Yan, T.P. Garrett, J.H. Liu, D.W. Rodgers, 
R.L. Garlick, G.E. Tart, Y. Husain, E.L. Reinherz, and S.C. 
Harrison. 1990. Atomic structure of  a fragment of  human CD4 
containing two immunoglobulin-like domains. Nature (lAnd.). 
348:411-418. 
44.  Moebius, U., P. Pallai,  S.C. Harrison, and E.L. Reinherz. 1993. 
Delineation of an extended surface  contact area on human CD4 
involved  in class II major histocompatibility complex binding. 
Pro~ Natl.  Acad. Sci. USA.  90:8259-8263. 
45.  Dintzis, H.M., R.Z. Dintzis, and B. Vogelstein. 1976. Molec- 
ular determinants of immunogenicity: the immunon model 
of immune response. Pro~ Natl. Acad. Sci. USA. 73:3671-3675. 
46.  Ullrich, A., and J. Schlessinger. 1990. Signal transduction by 
receptors with tyrosine kinase activity. Cell. 61:203-212. 
47.  Evavold,  RD., and P.M. Allen. 1991. Separation  of  IL-4  produc- 
tion from Th cell proliferation by an altered T cell receptor 
ligand. Science (Wash. DC).  252:1308-1310. 
48.  De Magistris, M.T.,  J. Alexander,  M. Coggeshall, A. Altman, 
F.C. Gaeta, H.M. Grey, and A. Sette. 1992. Antigen analog- 
major histocompatibility complexes act as antagonists of the 
T cell receptor. Cell. 68:625-634. 
49.  Racioppi, L., F. Konchese, L.A. Matis, and K.N. Germain. 
1993. Peptide-major histocompatibility complex class II com- 
plexes with mixed agnnistAntagonist properties provide evi- 
dence for ligand-rehted differences  in T cell  receptor-dependent 
intracellular signaling. J. Exit Meal. 177:1047-1060. 
50.  Sloan-Lancaster,  J., A.S. Shaw,  J.B. Rothbard, and P.M. Allen. 
1994. Partial T cell signaling: altered phospho-~"  and lack of 
ZAP-70 recruitment in APL-induced  T cell anergy. Cell. 79: 
913-922. 
51.  Madrenas,  J., R.L. Wange, J.L. Wang, N. Isakov,  L.E. Samel- 
son, and K.N. Germain. 1995. ~" phosphorylation without 
ZAP-70 activation induced by TCK antagonists or partial 
agonists. Science (Wash. DC).  267:515-518. 
52. Jameson, S.C., and M.J. Bevan. 1995. T ceU receptor antago- 
nists and partial agonists. Immunity.  2:1-12. 
53.  Germain, R.N., E.H. Levine, and J. Madrenas. 1995. The T 
cell receptor as a diverse signal transduction machine: molec- 
ular modds and implications for understanding T cell devel- 
opment and function.  The Immunologist. 3/4:97-105. 
787  K6nig  et al. 